StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Gastroenterology

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.11501